Selvita SA
Selvita SA is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through drug discovery and development services.
Business. Selvita SA is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange under the ticker symbol SLV1.WA. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
5 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Selvita SA is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in Poland and is primarily listed on the Warsaw Stock Exchange under the ticker symbol SLV1.WA. Specific details regarding its operating segments and geographic revenue mix are not available.
Selvita's capital structure is characterized by a debt-to-equity ratio of 0.53, indicating a moderate level of leverage. The company's liquidity position is reflected in a current ratio of 1.04, suggesting a balanced short-term liquidity profile. Free cash flow of 48.35 million PLN supports operational flexibility, though net cash is negative after subtracting total debt, signaling potential liquidity risk.
Profitability metrics show a return on equity of 0.25% and a return on assets of 0.14%, both below the typical thresholds for high-growth biotechnology firms. Operating income of 12.54 million PLN and a gross profit of 299.74 million PLN indicate a strong gross margin but limited net income conversion, with a net income of only 0.81 million PLN.
Geographically, Selvita's revenue is concentrated in its domestic market, with no disclosed international segments. This concentration may expose the company to local economic and regulatory risks. The company's business is driven by a single revenue stream, which could limit diversification benefits.
Growth trajectory is modest, with no specific revenue growth rates provided in the latest financial data. Capital expenditures of -7.08 million PLN suggest a reduction in investment, which may affect long-term growth potential. Analysts have assigned a mean price target of 45.45 PLN, with a median of 44.55 PLN, reflecting a cautious outlook.
Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could necessitate additional financing. No significant dilution sources are identified in the latest filings, and the dilution potential is assessed as low.
Recent events include the publication of the latest financial results, which show a slight improvement in operating income. No major regulatory or legal events have been disclosed in the latest filings. Analysts have issued four "buy" recommendations and no "strong buy" or "hold" ratings, indicating a generally positive but cautious sentiment.
- Selvita maintains a moderate debt-to-equity ratio of 0.53, suggesting a balanced capital structure.
- The company's return on equity and return on assets are below industry norms, indicating limited profitability.
- Revenue is concentrated in a single geographic market, increasing exposure to local economic conditions.
- Analysts have assigned a mean price target of 45.45 PLN, with a generally positive but cautious outlook.
- The company's liquidity position is medium risk, with a current ratio of 1.04 and negative net cash after debt.
- **margin_outlook_rationale**: Gross margin remains strong at 80.9%, but net margin is weak at 0.22%, driven by high operating expenses.
- **rd_outlook_rationale**: No specific R&D spending figures are disclosed, but the company's focus on drug discovery suggests ongoing investment in innovation.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,99 |
| Revenue | —no estimate | —no estimate | 391,6M PLN |
| Operating income | —no estimate | —no estimate | 30,4M PLN |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Selvita SA Market data — financials · 2026-05-29
- Selvita SA Market data — analyst estimates · 2026-05-29
Ownership & reference
Leadership
- Adrijana VinterMember of the Management Board
- Darius KurdasMember of the Management Board
- Dawid RadziszewskiMember of the Management Board